InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
23 juil. 2021 08h30 HE
|
InspireMD Inc.
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Announces Appointment of Katie Arnold to Board of Directors
12 mai 2021 06h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
29 avr. 2021 06h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by...
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
09 févr. 2021 06h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
03 févr. 2021 08h32 HE
|
InspireMD
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid...
InspireMD Announces Third Quarter 2020 Financial Results
09 nov. 2020 06h30 HE
|
InspireMD
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET TEL AVIV,...
UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
03 nov. 2020 07h53 HE
|
InspireMD
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
03 nov. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
13 oct. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
10 sept. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...